Why U.S. based Trividia Health is gaining traction in blood glucose testing with TRUE METRIX

Trividia Health, Inc. has announced that its TRUE METRIX Self-Monitoring Blood Glucose Meters and TRUE METRIX test strips have been named preferred products on the Express Scripts Commercial National Preferred Formulary, effective October 1, 2025. This formulary placement grants Trividia Health significant access to millions of commercially insured patients across the United States who rely on Express Scripts for pharmacy benefits, marking a pivotal milestone for the American diagnostics manufacturer.

The announcement underscores a broader trend in the diabetes care sector, where payers and pharmacy benefit managers are increasingly aligning with companies offering accurate, cost-effective, and supply-stable testing systems. Analysts tracking the diabetes technology market say this development positions Trividia Health for accelerated distribution growth, particularly among retail pharmacy chains and independent providers looking for trusted blood glucose monitoring solutions backed by domestic manufacturing and a national distribution footprint.

TRUE METRIX test strips are manufactured in Fort Lauderdale, Florida, leveraging Trividia Health’s U.S.-based production capabilities. The product portfolio uses proprietary Triple Sense Technology, which enhances blood sample analysis by capturing multiple sensing parameters per test. This focus on precision engineering, combined with widespread retail availability and value-based pricing, has helped the TRUE METRIX brand gain traction among both patients and healthcare professionals seeking consistency in diabetes monitoring.

With more than 40 years of experience, Trividia Health has built a reputation for reliability and innovation in the self-monitoring segment. Its latest alignment with Express Scripts reinforces its strategic goal of expanding access to high-quality diagnostics, especially as demand for accessible diabetes care continues to grow across both urban and rural markets in the United States.

How will Express Scripts formulary inclusion improve national access to diabetes diagnostics?

The inclusion of TRUE METRIX products on the Express Scripts Commercial National Preferred Formulary significantly alters the access landscape for diabetes patients managing their condition under commercial insurance plans. Express Scripts, one of the largest pharmacy benefit managers in the country, serves over 100 million Americans and plays a crucial role in determining which products patients are steered toward for routine monitoring.

With preferred status, TRUE METRIX devices and test strips will be offered with favorable pricing, streamlined coverage, and lower out-of-pocket costs compared to non-formulary options. This decision is expected to shift prescribing behavior among physicians and purchasing decisions among pharmacies. It also improves continuity of care, especially for patients who have previously struggled with formulary-driven meter switching or inconsistent access to test strips.

Payers and benefit managers are placing growing emphasis on product accuracy and patient compliance. The Triple Sense Technology in TRUE METRIX strips, which supports more reliable blood glucose readings, is seen as a key differentiator. Accurate readings not only improve clinical outcomes but also reduce downstream costs associated with mismanaged glucose levels. This aligns with the value-based care models being adopted by many payers across the country.

What makes Trividia Health’s U.S. manufacturing strategy a competitive edge in 2025?

At a time when global supply chain disruptions continue to impact the healthcare sector, Trividia Health’s ability to manufacture TRUE METRIX products in the United States has become a strategic asset. With operations centered in Fort Lauderdale, Florida, the diagnostics company benefits from tighter quality control, faster distribution lead times, and resilience against international logistics issues.

For Express Scripts and other pharmacy benefit managers, domestic sourcing offers greater security in terms of product availability and fulfillment reliability. This becomes particularly important in high-frequency categories such as diabetes testing, where any interruption in supply can have immediate clinical consequences for patients.

The value of a U.S.-based production model also resonates with retail pharmacy partners and distributors who are increasingly under pressure to reduce backorders and maintain fully stocked shelves. In an environment where many test strip suppliers rely heavily on overseas production, Trividia Health stands out as a vertically integrated, high-volume U.S. manufacturer capable of serving both branded and private-label markets.

Why are payers prioritizing performance and affordability in self-monitoring devices?

The decision to include TRUE METRIX on the preferred formulary reflects a broader shift among payers and benefit managers who are increasingly scrutinizing the performance-to-cost ratio of diabetes monitoring products. Analysts following formulary trends note that pharmacy benefit managers are not only looking for cost savings but are also focused on reducing variability and improving patient adherence.

Devices like the TRUE METRIX meters, which combine advanced biosensor engineering with affordable pricing, offer a sweet spot for formulary inclusion. Trividia Health’s emphasis on delivering scientifically validated performance through Triple Sense Technology has helped it stand apart in a crowded field of self-monitoring solutions.

The move also suggests that pharmacy benefit managers are aiming to streamline device ecosystems within their plans to reduce administrative burden. Consolidating formularies around dependable brands simplifies patient onboarding and minimizes the confusion that arises from product switches due to formulary changes.

How does retail pharmacy integration support Trividia Health’s formulary momentum?

Trividia Health’s products are available under the TRUE METRIX brand and also sold through private-label agreements with major retail pharmacy chains, distributors, and independent pharmacies across the United States. This wide-reaching presence allows for immediate scalability once a preferred formulary placement goes into effect.

For Express Scripts members, this means greater convenience and fewer access hurdles. Patients can find TRUE METRIX-compatible meters and test strips at thousands of local pharmacy locations without needing to special-order or wait for insurance approvals on alternative brands.

This extensive retail penetration, backed by a strong distribution network, ensures that the formulary decision translates into actual uptake. It also supports Trividia Health’s strategy of pairing national coverage with local availability, reinforcing its positioning as a go-to diagnostics provider in the self-monitoring segment.

Executives at Trividia Health have highlighted the importance of this dual coverage approach, suggesting that it enables the organization to support both payer mandates and patient-centric convenience. As the diabetes population in the U.S. continues to rise, ease of access is expected to become an increasingly decisive factor in patient outcomes.

What are the broader market signals from this formulary inclusion for diabetes diagnostics?

While Trividia Health is privately held and does not release quarterly earnings, market observers view formulary decisions as reliable indicators of institutional sentiment. A preferred listing on the Express Scripts formulary is often seen as a precursor to broader adoption across employer-sponsored plans, regional insurers, and Medicare Advantage programs.

Analysts also anticipate potential spillover effects into adjacent diagnostic categories, where payers may adopt similar criteria for inclusion: namely, U.S.-based production, demonstrated accuracy, cost containment, and scalable retail reach.

For competitors in the blood glucose monitoring market, this move raises the bar. Pharmacy benefit managers are becoming more selective, and smaller diagnostics companies may struggle to compete without equivalent manufacturing scale or payer relationships.

Healthcare technology analysts expect further formulary reshuffles as pharmacy benefit managers continue to reassess their diabetes care strategies in 2026 and beyond. Companies that combine robust engineering with low-friction distribution will likely lead the next wave of inclusion.

What are the strategic implications for Trividia Health’s long-term diagnostics portfolio?

The inclusion of the TRUE METRIX line on Express Scripts’ commercial formulary represents a pivotal validation point for Trividia Health’s broader portfolio and roadmap. Beyond the current product range, the company has been active in developing digital health integrations and advanced monitoring platforms that combine self-testing with data sharing capabilities.

Market analysts say this formulary milestone gives Trividia Health the institutional credibility to approach other large benefit managers and health systems with expanded offerings. It may also lead to increased demand from retail chains seeking reliable, scalable testing platforms for private-label rollouts.

By maintaining its U.S. production base and expanding payer partnerships, Trividia Health is signaling that it aims to be more than just a glucose meter supplier. The company appears to be laying the foundation for broader health and wellness diagnostics leadership, particularly in chronic condition management.

What are the key takeaways from Trividia Health’s TRUE METRIX preferred placement with Express Scripts?

• Trividia Health, Inc. has secured preferred status for its TRUE METRIX Self‑Monitoring Blood Glucose Meters and test strips on the Express Scripts Commercial National Preferred Formulary beginning October 1, 2025.

• The preferred listing improves affordability and access for millions of commercially insured patients who rely on Express Scripts pharmacy benefit services across the United States.

• The TRUE METRIX portfolio uses Triple Sense Technology to support accurate and consistent readings, a factor that aligns with payer priorities for high‑performance medical devices.

• Trividia Health’s U.S. manufacturing base in Fort Lauderdale, Florida strengthens its position by providing supply chain resilience and domestic production capacity.

• The diagnostics company’s strong retail presence across national drugstores, distributors, and independent pharmacies supports rapid adoption once formulary changes take effect.

• Analysts say the formulary decision reflects broader market trends that favor affordable, reliable, and locally manufactured diabetes monitoring solutions.

• The milestone may lead to expanded payer partnerships and stronger placement across employer plans, regional insurers, and future commercial formularies.

• The preferred status enhances Trividia Health’s strategic visibility as a long‑term player in accessible, high‑accuracy diabetes diagnostics.